U.S. markets open in 8 hours 26 minutes
  • S&P Futures

    4,540.25
    +16.00 (+0.35%)
     
  • Dow Futures

    35,036.00
    +126.00 (+0.36%)
     
  • Nasdaq Futures

    15,100.75
    +67.25 (+0.45%)
     
  • Russell 2000 Futures

    2,065.10
    +5.90 (+0.29%)
     
  • Crude Oil

    87.27
    +0.31 (+0.36%)
     
  • Gold

    1,839.60
    -3.60 (-0.20%)
     
  • Silver

    24.23
    -0.01 (-0.02%)
     
  • EUR/USD

    1.1353
    +0.0006 (+0.06%)
     
  • 10-Yr Bond

    1.8270
    0.0000 (0.00%)
     
  • Vix

    23.85
    +1.06 (+4.65%)
     
  • GBP/USD

    1.3626
    +0.0014 (+0.10%)
     
  • USD/JPY

    114.4780
    +0.1250 (+0.11%)
     
  • BTC-USD

    41,919.80
    +156.30 (+0.37%)
     
  • CMC Crypto 200

    995.42
    +0.67 (+0.07%)
     
  • FTSE 100

    7,589.66
    +26.11 (+0.35%)
     
  • Nikkei 225

    27,790.46
    +323.23 (+1.18%)
     

Celsion Corporation to Hold First Quarter 2019 Financial Results Conference Call on Wednesday, May 15, 2019

  • Oops!
    Something went wrong.
    Please try again later.
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

LAWRENCEVILLE, N.J., April 12, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter ended March 31, 2019 and provide an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin and GEN-1, an IL-12 DNA plasmid vector formulated into a nanoparticle with a non-viral delivery system at 11:00 a.m. EDT on Wednesday, May 15, 2019.

The call will be archived for replay and will be available on the Company’s website, www.celsion.com, for 90 days after 2:00 p.m. ET on Wednesday, May 15, 2019.

About Celsion Corporation

Celsion is a fully-integrated oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The Company's lead program is ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer and in development for other cancer indications. The Company’s product pipeline also includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer. Celsion has two platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. For more information on Celsion, visit our website: http://www.celsion.com. (CLSN-FIN).

Celsion Investor Contact


Jeffrey W. Church
Executive Vice President, CFO
and Corporate Secretary
609-482-2455
jchurch@celsion.com